RxDoctor Payments DataLook up a doctor →

Nicholas Camps, DO

Infectious Disease · Miami Beach, FLNPI 1720320955

Payments from drug & device makers

$97,928in general payments, 2019–2025

Across 747 payments — averaging $131.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$78K
  • AbbVie$11K
  • Gilead$4K
  • Insmed, Inc.$1K
  • Johnson & Johnson$860
  • Merck$805
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$1,0501%
  • Speaking & faculty fees$70,79572%
  • Travel & lodging$7,1507%
  • Food & beverage$18,41919%
  • Education$5141%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$97,928 in reported general payments places this provider in the 90th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$97,076
Medicare patients
224
Services billed
766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala290$1,194,256
DovatoDolutegravir Sodium/Lamivudine197$628,120
TivicayDolutegravir Sodium161$431,727
PrezcobixDarunavir/Cobicistat128$326,448
RukobiaFostemsavir Tromethamine29$299,548
TriumeqAbacavir/Dolutegravir/Lamivudi56$222,751
JulucaDolutegravir/Rilpivirine54$211,739
DescovyEmtricitabine/Tenofov Alafenam70$168,368
OdefseyEmtricitab/Rilpiviri/Tenof Ala30$120,749
GenvoyaElviteg/Cob/Emtri/Tenof Alafen20$78,352
Maraviroc34$57,116
PrezistaDarunavir15$36,683
Isentress HdRaltegravir Potassium12$23,962
IntelenceEtravirine12$17,586
Ritonavir17$1,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Tivicay, Rukobia, Triumeq, Juluca$77,819$1,793,885497 claims
GileadBiktarvy, Descovy, Genvoya$3,963$1,440,976380 claims
Johnson & JohnsonPrezcobix$860$326,448128 claims
MerckIsentress Hd$805$23,96212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →